Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Daré Bioscience, Inc. (NASDAQ: DARE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports when available, and exhibits such as press releases and corporate presentations that the company uses to communicate material information about its operations and strategy.
Daré’s recent 8-K filings illustrate several key themes. Some reports furnish earnings press releases and corporate updates, outlining financial results, cash position, research and development spending and the status of programs such as DARE to PLAY Sildenafil Cream, Ovaprene and other pipeline assets. Other 8-Ks describe interim clinical data for Ovaprene’s pivotal Phase 3 study, including data safety monitoring board recommendations and information on pregnancy rates, tolerability and study design.
Additional 8-K filings address corporate and listing matters, such as Nasdaq correspondence regarding compliance with Listing Rule 5550(b) for stockholders’ equity and market value of listed securities, and the company’s multi-step plan to maintain its listing on The Nasdaq Capital Market. There are also filings related to stock incentive plan amendments and stockholder meeting results, which provide detail on governance decisions and equity compensation arrangements.
Through Stock Titan, users can review Daré’s SEC filings in one place and use AI-powered tools to summarize complex documents. These tools can help explain the implications of items such as clinical trial updates, grant agreements, listing notices and capital-raising activities. Investors interested in Daré’s women’s health portfolio, regulatory status and financing strategy can use this page to monitor new 8-Ks and other filings as they are posted to EDGAR, and to quickly interpret how those disclosures relate to the company’s pipeline and commercialization plans.
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units. The company issued 43,050 Investor Units at an offering price of $5.00 per unit, each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
These 43,050 Investor Units include 43,050 shares of Series A Preferred Stock and Investor Warrants to purchase up to 86,100 shares of Daré’s common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on January 5, 2026, and an offering circular dated January 6, 2026.
Daré Bioscience, Inc. reported completing the second closing of its ongoing Regulation A equity offering. The program allows sales of up to 4,854,000 Investor Units, each priced at $5.00 and made up of one share of Series A Convertible Preferred Stock and two common stock warrants.
In this second closing on March 6, 2026, Daré issued 17,500 Investor Units, consisting of 17,500 shares of Series A Preferred Stock and Investor Warrants to purchase up to 35,000 shares of common stock. The offering is made under a Form 1-A offering statement qualified on January 5, 2026.
Daré Bioscience, Inc. furnished a current report to let investors know it has posted an updated corporate presentation on its investor relations website. The presentation is dated March 2, 2026 and is also attached as Exhibit 99.1 to the report for convenient access.
The company states that this investor presentation is being furnished under Regulation FD, not filed, which means it is not subject to certain securities law liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. No financial results or new transaction details are described in the excerpt.
Dare Bioscience director and CEO Sabrina Martucci Johnson reported an acquisition of preferred stock and warrants tied to a Regulation A unit purchase. She subscribed on February 18, 2026 to purchase 10,800 Investor Units at $5 per Unit, with issuance to occur when the company accepts her subscription.
Each Unit includes one share of Series A Convertible Preferred Stock, initially convertible into two shares of common stock, plus two warrants, each to purchase one share of common stock. The preferred stock is perpetual, while the warrants become exercisable any time after issuance and expire 36 months after issuance, giving her long-dated, equity-linked exposure to the company.
Dare Bioscience, Inc. reported that Chief Executive Officer and director Sabrina Martucci Johnson received an employee stock option grant covering 172,000 shares of common stock on January 30, 2026. The option has an exercise price of $1.81 per share and was granted at a price of $0 per option.
The option vests in 48 equal monthly installments, beginning on the one-month anniversary of the grant date, as long as she continues to provide service to the company. After this grant, she directly holds 172,000 such derivative securities.
Dare Bioscience, Inc. reported that its Chief Accounting Officer, MarDee Haring-Layton, received an employee stock option grant. The award covers 49,000 options to purchase common stock at an exercise price of $1.81 per share, granted on January 30, 2026.
The option vests in 48 equal monthly installments starting one month after the grant date, conditioned on her continuous service with the company. Following this grant, she holds 49,000 derivative securities directly in the form of these stock options.
Daré Bioscience created a new Series A Convertible Preferred Stock and launched a Regulation A offering of preferred stock and warrant units. The company designated 4,999,620 shares of preferred stock with a $5.00 stated value, no dividends, and senior liquidation rights over common stock.
Each preferred share is initially convertible at the holder’s option into two shares of common stock at a $2.50 conversion price, with forced conversion possible after a change in control or specified stock price and financing triggers. Daré may redeem preferred shares any time starting three years after the initial closing at the lower of stated value plus an 8% annual return or 200% of stated value.
The Regulation A offering covers up to 4,854,000 Investor Units at $5.00 per unit, each unit consisting of one preferred share and two warrants to buy common stock at $4.00 per share. The initial closing issued 5,090 Investor Units and related placement compensation, including a 7.25% selling fee and Agent Unit Warrants equal to 3% of units sold.
Daré Bioscience, Inc. reported that it has posted an updated corporate presentation in the Investors section of its website as of January 6, 2026. The same presentation, dated January 6, 2026, is also included as Exhibit 99.1 to this report and incorporated by reference for informational purposes. The company notes that this material is being furnished rather than filed under securities laws, which limits how it is treated for liability and incorporation into other regulatory documents. Information available on or through the company’s website, including the presentation, is not automatically incorporated into this report.
Daré Bioscience reported Q3 2025 results showing minimal revenue and a narrower quarterly loss. Total revenue was $2,262, driven by royalty revenue, while operating expenses fell to $3.67 million, down from $4.72 million a year ago, reflecting lower research and development spending.
Net loss for the quarter was $3.56 million, improving from a $4.70 million loss in Q3 2024. Cash and cash equivalents were $23.08 million at September 30, 2025, up from $15.70 million at year-end, aided by equity financing. The company sold 4,329,116 shares under its March 2023 ATM for gross proceeds of approximately $18.0 million (about $17.6 million net) and 900,000 shares under its Lincoln Park agreement for roughly $2.0 million in net proceeds.
Liquidity remains a key risk. Management disclosed substantial doubt about the company’s ability to continue as a going concern within 12 months, citing ongoing losses, negative operating cash flow, and uncertainty around timing and magnitude of revenue from its Section 503B compounding and consumer health strategies. As of November 12, 2025, 14,289,229 common shares were outstanding.